^
Association details:
Biomarker:No biomarker
Cancer:Hodgkin Lymphoma
Regimen:R-CVP (cyclophosphamide + + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/14/2020
Excerpt:
Hodgkin Lymphoma: NLPHL, second-line options added:…R-CVP...